NYSE · ZBH
Zimmer Biomet Holdings, Inc.
Healthcare · Medical - Devices
$98.56▼ 0.25% ($0.25)at close
As of 4:00 PM ET
Market cap
$18.80B
P/E
23.55
EPS (TTM)
$4.18
Next earnings
Nov 4, 2026
Valuation
Cash-flow DCF
Verdict: cheap. Price below all scenarios.
The price holds with free cash flow shrinking 17.4% a year for 5 years. Our scenarios assume −4.4–25.0%.
That's below its past 10-year pace of 10.6%.
Value per share
Base case
$494.22
Price used $98.56 is 80% below this
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
3 more notes
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Market beta (0.48) is below the minimum default of 0.5 — short lookback windows can understate systematic risk. Beta floored at 0.5 for default assumptions; adjust manually if needed.
This estimate is at least 3× the price used. Review the assumptions behind the gap.
Free cash flow each value needs
Free cash flow today $1.9B. The price needs $973M by 2036. Base case: $4.2B. At its recent pace: $5.2B. Bear to Bull: $1.8B to $11.1B.
Free cash flow today $1.9B. The price needs $973M by 2036. Base case: $4.2B. At its recent pace: $5.2B. Bear to Bull: $1.8B to $11.1B.
Free cash flow in 2036
today $1.9B
−$3.2Bless than the Base case
Value per share · Base case
$494.22
Price $98.56
80% below this
- Stage 1 growth, yrs 1–5
- 10.6%
- Stage 2 growth, yrs 6–10
- 5.8%
- Discount rate
- 6.0%
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
3 more notes
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Market beta (0.48) is below the minimum default of 0.5 — short lookback windows can understate systematic risk. Beta floored at 0.5 for default assumptions; adjust manually if needed.
This estimate is at least 3× the price used. Review the assumptions behind the gap.
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 4.46% over the last year. Revenue grew 8.62% over the trailing twelve months. Operating margin moved from 16.09% to 15.73%. Free cash flow grew 28.52% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 15.73%. A decisive move in revenue — currently up 8.62% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products.
Market multiples
Stock splits
Every 100 shares became 103
Profitability & growth
Analyst consensus
17
Buy
22
Hold
3
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 4, 2026
Q3 FY26 · EPS est $1.88 · Revenue est $2.0B
Same quarter, year over year
FY26 YTD +7.2%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $4.16 vs $3.88 · 1 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $8.20
- +2.5%
- FY24
- $8.00
- —
Q2 FY26
Reported Aug 5, 2026 · Latest
HoverTap a cell to inspect
Actual
$2.07
Estimate
$2.01
Year over year
0.0%
Vs prior quarter
-1.0%
Institutional Sentiment
Zimmer Biomet Holdings, Inc. · ZBH
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.